SEC Comment Letter 0000000000-23-004431 to Lite Strategy, Inc. (LITS)
Lite Strategy, Inc.
Date: May 1, 2023 · CIK: 0001262104 · Accession: 0000000000-23-004431
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271481
Letter
United States securities and exchange commission logo May 1, 2023 Daniel P. Gold President and Chief Executive Officer MEI Pharma, Inc. 11455 El Camino Real, Suite 250 San Diego, California 92130 Re:MEI Pharma, Inc. Registration Statement on Form S-4 Filed April 28, 2023 File No. 333-271481 Dear Daniel P. Gold: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Steven Navarro
Show Raw Text
United States securities and exchange commission logo
May 1, 2023
Daniel P. Gold
President and Chief Executive Officer
MEI Pharma, Inc.
11455 El Camino Real, Suite 250
San Diego, California 92130
Re:MEI Pharma, Inc.
Registration Statement on Form S-4
Filed April 28, 2023
File No. 333-271481
Dear Daniel P. Gold:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Steven Navarro